In Chengdu, China, C-Ray Therapeutics (Chengdu) Co., Ltd. underwent on-site inspections on June 23, 2026, led by experts from the Sichuan Provincial Center for Drug Evaluation and the National Defense Science and Industry. This marked a significant milestone for the company, which aims to secure approvals and certifications for its products. The detailed examination by the expert panel is crucial for ensuring compliance with stringent regulations in the pharmaceutical sector. The inspection process involved evaluating various aspects of the company’s operations, with a focus on adherence to safety standards, efficacy, and quality control measures. C-Ray Therapeutics anticipates that successful completion of the inspections will pave the way for advancing its drug development initiatives.